• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    DocGo Inc. filed SEC Form 8-K: Regulation FD Disclosure

    6/12/25 4:22:48 PM ET
    $DCGO
    Medical/Nursing Services
    Health Care
    Get the next $DCGO alert in real time by email
    dcgo-20250612
    0001822359FALSE00018223592025-06-122025-06-12


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ___________________________________

    FORM 8-K
    ___________________________________

    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (date of earliest event reported): June 12, 2025
    ___________________________________

    DOCGO INC.
    (Exact name of registrant as specified in its charter)
    ___________________________________

    Delaware
    001-39618
    85-2515483
    (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
    685 Third Avenue, 9th Floor, New York, New York
    10017
    (Address of principal executive offices)
    (Zip Code)
    (844) 443-6246
    (Registrant's telephone number, including area code)
    N/A
    (Former name or former address, if changed since last report)
    ___________________________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading Symbol
    Name of each exchange on which registered
    Common stock, par value $0.0001 per shareDCGOThe Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

    Emerging growth company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 7.01 Regulation FD Disclosure.

    On June 12, 2025, the Board of Directors of DocGo Inc. (the “Company”) approved an extension of the expiration date of the Company’s current share repurchase program (“Repurchase Program”) from June 30, 2025 to December 31, 2025. As previously disclosed, pursuant to the Repurchase Program, the Company may purchase up to $26 million in shares of the Company’s common stock. Other than the extension of the program’s expiration date, no changes were made to the Repurchase Program.

    Under the terms of the Repurchase Program, as extended, the Company may continue to purchase shares of its common stock on a discretionary basis from time to time through open market repurchases or privately negotiated transactions or through other means, including by entering into Rule 10b5-1 trading plans or accelerated share repurchase programs, in each case, during an “open window” and when the Company does not possess material non-public information.

    The timing and actual number of shares repurchased under the Repurchase Program will depend on a variety of factors, including stock price, trading volume, market conditions, corporate and regulatory requirements and other general business considerations. The Repurchase Program may be modified, suspended or discontinued at any time without prior notice.

    Repurchases under the Repurchase Program may be funded from the Company’s existing cash and cash equivalents, future cash flow or proceeds of borrowings or debt offerings.

    The information in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.
    1


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    DOCGO INC.
    By:
    /s/ Norman Rosenberg
    Name:
    Norman Rosenberg
    Title:
    Chief Financial Officer and Treasurer

    Date: June 12, 2025


    2
    Get the next $DCGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DCGO

    DatePrice TargetRatingAnalyst
    5/9/2025Buy → Neutral
    BTIG Research
    2/28/2025$5.00 → $2.85Buy → Hold
    Deutsche Bank
    8/18/2023$15.00Buy
    BTIG Research
    4/21/2023$11.00Overweight
    Cantor Fitzgerald
    4/19/2022$11.00Buy
    Deutsche Bank
    1/19/2022$14.00Buy
    Stifel
    12/21/2021$13.00Buy
    Canaccord Genuity
    12/7/2021$14.00Buy
    Needham
    More analyst ratings

    $DCGO
    SEC Filings

    See more
    • DocGo Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - DocGo Inc. (0001822359) (Filer)

      6/18/25 4:21:01 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - DocGo Inc. (0001822359) (Filer)

      6/12/25 4:22:48 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by DocGo Inc.

      10-Q - DocGo Inc. (0001822359) (Filer)

      5/8/25 4:35:04 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care

    $DCGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Burdiek Michael J bought $13,300 worth of shares (10,000 units at $1.33), increasing direct ownership by 2% to 641,560 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/23/25 4:25:30 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Director Burdiek Michael J bought $21,450 worth of shares (15,000 units at $1.43), increasing direct ownership by 2% to 631,560 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/15/25 5:05:47 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Director Klasko Stephen K. M.D. bought $22,350 worth of shares (15,000 units at $1.49) (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/14/25 5:42:40 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care

    $DCGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Burdiek Michael J bought $13,300 worth of shares (10,000 units at $1.33), increasing direct ownership by 2% to 641,560 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/23/25 4:25:30 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Director Burdiek Michael J bought $21,450 worth of shares (15,000 units at $1.43), increasing direct ownership by 2% to 631,560 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/15/25 5:05:47 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Chief Executive Officer Bienstock Lee covered exercise/tax liability with 15,565 shares, decreasing direct ownership by 0.79% to 1,955,514 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/15/25 5:03:33 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care